NewLimit raises $130 million in Series B financing

NewLimit, a US biotech start-up dedicated to extending human lifespan through gene reprogramming, has raised $130 million in a Series B funding round.

In its press release, the company stated: “NewLimit was founded to develop medicines that add healthy years to each human life. Initially, we thought it would take many years to show progress toward this goal.

“We’re proud that our team achieved this milestone faster than we expected. Based on these results, we’ve raised a $130 million Series B led by Kleiner Perkins alongside new investors Nat Friedman/Daniel Gross, Khosla Ventures, Human Capital, and Valor Equity Partners - joined by existing investors Dimension, Founders Fund, and Brian Armstrong. We also raised from some of the best angels who have supported the company over the first two years including John and Patrick Collison, Fred Ehrsam, Elad Gil, Joshua Kushner, Joe Lonsdale, and Garry Tan.”